Percutaneous left atrial appendage closure using a modified single-operator-technician approach under deep sedation: A single-center experience.

Background: Historically, percutaneous transcatheter left atrial appendage closure (LAAC) has been performed under general anesthesia (GA) with transesophageal echocardiographic images obtained by a noninvasive cardiologist and usually requires an overnight hospital stay. Alternatively, we present our single-center experience performing LAACs under deep sedation (DS), employing an echocardiographic technician instead of a noninvasive cardiologist, and expediting same-day discharge. Mid- to long-term outcomes were also evaluated with follow-up imaging at a 45-day visit.

Radiation doses to the breast and predicted breast cancer risk among patients treated for Hodgkin lymphoma with modern radiotherapy.

Purpose: To contrast breast radiation exposure from chest radiotherapy in 2006-2021 with 1965-1997, and to compare breast cancer (BC) risk 25 years after treatment predicted by two models.

Methods: Radiation dose distributions to the breast from 101 chest radiotherapies given 2006-2021 for Hodgkin lymphoma (HL) or other lymphoma in one German and two Dutch hospitals were compared with doses received by 505 Dutch HL patients treated 1965-1997 and sampled into a nested case-control study, weighted to represent a HL patient cohort. Dose-volume histograms, mean dose and doses to 10 breast segments were evaluated.

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Purpose: To evaluate the survival benefit of chemotherapy intensification in older patients with AML who have not achieved a measurable residual disease (MRD)-negative remission.

Methods: Five hundred twenty-three patients with AML (median age, 67 years; range, 51-79) without a flow cytometric MRD-negative remission response after a first course of daunorubicin and AraC (DA; including 165 not in remission) were randomly assigned between up to two further courses of DA or intensified chemotherapy-either fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC).

Results: Overall survival (OS) was not improved in the intensification arms (DAC DA: hazard ratio [HR], 0.

Identifying the Next Generation of Academic Surgeons and Physician Leaders.

Many highly competitive academic general surgery residency programs share the mission of training the next generation of academic surgeons. There is a widely held belief that encouraging publications throughout residency will promote sustained research productivity and facilitate a pathway into an academic career. Consequently, the total number of publications is one of the strongest predictors for resident selection among top ranked general surgery programs.

Relapsed AML in a Patient Presenting to a College Health Center: A Case Report.

Acute myelogenous leukemia (AML) represents nearly 40% of all cancers affecting the adolescent and young adult (AYA) population. Although overall survival has improved, cure rates for AYAs lag behind younger leukemia patients. The primary care provider (PCP), including the college health provider, is a crucial member of the medical team for children and AYA cancer survivors.